Project Grant R01HL170575
Award Date
7/17/24
Completion Date
6/30/29
Dollars Obligated
$2.2M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
This Project Grant award, valued at $159,512.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research to uncover effective strategies for mitigating the detrimental effects of cardiac fibrosis, a prominent hallmark of dilated cardiomyopathy (DCM), an inherited heart disease. The key products and services to be delivered include: 1) validating and describing the...
The University of Arizona was awarded a $1,309,340.00 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on disruption of the cardiac-coronary axis as a mechanism of heart failure with preserved ejection fraction (HFpEF). The 4-year grant, beginning on July 1, 2024 and ending on May 31, 2028, will support an interdisciplinary research approach encompassing molecular, cellular, vascular...
This Project Grant award in the amount of $699,133 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance the understanding of heart failure with preserved ejection fraction (HFPEF), a condition affecting approximately 3 million Americans. The research will map the epigenomic and transcriptomic regulatory landscape across multiple organs, including the heart, kidney, and liver, to investigate the molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837) provides $1,088,500.00 to The University of Iowa to conduct research on genetic and molecular mechanisms of heart disease. The research program consists of three independent projects: 1) defining microRNA targeting events and their biological relevance in the heart, including the clinical significance of genetic variants that alter...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $605,253 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Delaware. The grant, titled "DISSECTING THE PROTECTIVE ROLE OF CARDIAC HSP90SS ABLATION/INHIBITION", aims to examine the protective role of the cardiac protein HSP90B and identify mechanisms underlying its potential cardioprotective effects, particularly related to mitochondrial membrane integrity. Over the 5-year...
This $601,563 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to investigate the pathogenic roles and molecular mechanisms of histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure. The key objectives are to: 1) determine the mechanisms by which deleting KDM5A and KDM5B improves cardiac function and survival in a mouse model of dilated...
This $2,304,645 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to develop cardiac-targeted lipid nanoparticles (CLNPs) for delivering inhibitory RNA cargos to treat contractile dysfunction in heart failure. The research aims to: 1) characterize the on- and off-target effects of CLNPs carrying different inhibitory nucleic acids in healthy rats and human myocardium, 2) determine if...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating early onset diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to fully characterize three specific functional domains of the cardiac thin filament linked to the regulation of relaxation, determine...
This federal Project Grant award for $248,999 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research aimed at identifying new therapeutic pathways for dilated cardiomyopathy (DCM), a leading cause of heart failure. The primary objectives are to: 1) study the mechanisms by which specific microRNAs can ameliorate contractile defects in induced pluripotent stem cell-derived cardiomyocytes carrying DCM-causing...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,454,955 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Beckman Research Institute of the City of Hope. The grant will fund research to characterize the role of the RPS6KB1 kinase in adaptive cardiac hypertrophy and heart failure progression, with a focus on understanding the interplay between RPS6KB1 phosphorylation by ERK and ubiquitination. The research aims to elucidate novel mechanisms...